<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02958527</url>
  </required_header>
  <id_info>
    <org_study_id>B2411278</org_study_id>
    <nct_id>NCT02958527</nct_id>
  </id_info>
  <brief_title>Drug Use Investigation Of Effexor (SECONDARY DATA COLLECTION STUDY; SAFETY AND EFFICACY OF EFFEXOR.UNDER JAPANESE MEDICAL PRACTICE)</brief_title>
  <official_title>Drug Use Investigation Of Effexor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SECONDARY DATA COLLECTION STUDY; SAFETY AND EFFICACY OF EFFEXOR.UNDER JAPANESE MEDICAL
      PRACTICE
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted under the central registration system until the number of
      subjects who meet the conditions for registration reaches the target number of subjects. 12
      weeks from the start date. The patients who completed the 12-week treatment with this product
      will be observed up until Week 52.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with adverse events</measure>
    <time_frame>12 weeks from the start date (up until 52 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hamilton Rating Scale for Depression</measure>
    <time_frame>12 weeks from the start date ( up until 52 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery - Asberg Depression Rating Scale</measure>
    <time_frame>12 weeks from the start date ( up until 52 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions</measure>
    <time_frame>12 weeks from the start date ( up until 52 weeks)</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Depression/Depressed State</condition>
  <arm_group>
    <arm_group_label>venlafaxine</arm_group_label>
    <description>Patients with no experience of using time Effexor(venlafaxine) who will be administered time Effexor(venlafaxine)for the first</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venlafaxine</intervention_name>
    <description>The usual adult starting dosage for oral use is 37.5 mg of venlafaxine once daily, which is increased to 75 mg once daily after a meal from 1 week later. The dose may be adjusted within a range not exceeding 225 mg/day according to the patient's age and symptoms. However, the dose should be increased by 75 mg/day at intervals of not less than 1 week.</description>
    <arm_group_label>venlafaxine</arm_group_label>
    <other_name>Effexor</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients who meet the inclusion criteria and who were registered to this study within
        14 days including the start date of treatment with this product will be subjects for this
        study
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with no experience of using this product who will be administered this
             product for the first time

        Exclusion Criteria:

          -  Exclusion criteria are not provided in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2411278&amp;StudyName=Drug+Use+Investigation+Of+Effexor</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2411278&amp;StudyName=Drug+Use+Investigation+Of+Effexor+Non-interventional+%28ni%29+Study+Protocol</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2016</study_first_submitted>
  <study_first_submitted_qc>November 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2016</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Effexor</keyword>
  <keyword>Depression</keyword>
  <keyword>Depressed state</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

